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of metabolism. What is novel and exciting
in the work of Buch et al. (2008) is the com-
bination of gene regulation studies, endo-
crinology, and physiology in a model ge-
netic organism whose genome and gene
regulatory linkages can be readily com-
pared to the human genome.
The significance of these results for
human biology is indeed compelling. Mu-
tations in the acid a-glucosidase gene
(GAA) are the basis for Pompe disease,
or glycogen storage disease II, in which
a lack of a-glucosidase activity in lyso-
somes results in destructive glycogen ac-
cumulation (Hirschhorn, 1995). Though
now treatable with enzyme replacement,
unmanaged the disease pathology can
present devastating cardiac and skeletal
muscle weakness, and, in its infantile-on-
set forms, heart failure may result. On the
other hand, a-glucosidase inhibitors are a
widely used oral medication for type 2 dia-
betes mellitus (van de Laar et al., 2005).
These inhibitors acton intestinala-glucosi-
dase to block the hydrolysis of complex
carbohydrates, resulting in slowed uptake
of glucose and other monosaccharides
and decreased postprandial demands for
pancreatic b cell insulin secretion.
Remarkably, this strategy of unburden-
ing insulin-producing b cells from high
levels of sustained insulin secretion may
already be wired into the neuroendocrine
control of dietary carbohydrate uptake
in Drosophila. Indeed, the expression of
tobi in the gut would support such a role,
linking high-carbohydrate diet to reduced
uptake of sugar, though this has not yet
been tested. It is most likely that fat body
expression of tobi facilitates release of
glucose stores when insulin signaling,
CC cell activity, and protein synthesis are
elevated. This characteristic corelease of
insulin and glucagon in response to amino
acids is also anobserved feature of human
islet biology (Unger andOrci, 1994). Given
the accumulating parallels between the
islet-like cells of Drosophila and the pan-
creatic islets of mammals, it would not
be surprising if this homeostatic mecha-
nism, and possibly others yet to
be found, is evolutionarily conserved be-
tween flies and humans.
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Enhanced and deficient immune responses are associated with abnormal bone homeostasis. A new study by
Shinohara et al. (2008) shows that protein phosphorylation by the tyrosine kinases Bruton and Tec links im-
munity and bone as well as two signaling pathways in precursors of osteoclasts, the cells that degrade bone.A strong, healthy skeleton enables mobil-
ity and is especially important for the
growing number of aging individuals who
will live long enough to develop osteopo-
rosis. Fewpeople are aware that the yearly
incidence of osteoporotic fractures in
women is greater than that of heart
attacks, strokes, and breast cancer com-
bined. What’s more, osteoporosis can
complicate autoimmune diseases such
as rheumatoid arthritis, in which immuneresponses are enhanced, andcanalsooc-
cur in patients with immunodeficiencies.
Suchpatients are thereforeat evengreater
risk of developing osteoporotic fractures
as they age. Recent findings by Shinohara
et al. (2008) provide links between com-
mon and immune causes of osteoporosis
as well as the signaling mechanisms that
induce osteoclast formation.
Bone health is maintained by the
process of bone remodeling, in whichCell Metabtrenches are dug on the surfaces of the
spongy bone in marrow cavities by osteo-
clasts and then filled with new bone
by bone-building osteoblasts. Osteopo-
rosis occurs when the amount of bone
removed by osteoclasts exceeds that
laid down by osteoblasts. Conversely, os-
teopetrosis occurs during embryonic de-
velopment when osteoclast formation or
function is defective and bones become
denser (Karsenty and Wagner, 2002).olism 7, April 2008 ª2008 Elsevier Inc. 283
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PreviewsFigure 1. Osteoclast Differentiation through Cytokines and Costimulatory Complexes
In normal or disease states, osteoblasts and immune cells such as activated T cells produce RANKL or
unknown ligands that activate two distinct signaling pathways in osteoclast precursors. (1) RANK forms
a complex with TNF receptor-associated factor 6 (TRAF6), leading to activation of the canonical NF-kB
pathway and upregulation of c-Fos and NFATc1 expression. RANKL also stimulates the phosphorylation
of PLCg by activating Btk/Tec tyrosine kinases through RANK. It is not known whether Btk/Tec bind to
TRAF6. (2) Formation of theOSCAR/FcRg costimulatory complex leads to the phosphorylation of the scaf-
fold protein BLNK through ITAM-associated Syk, which is a prerequisite for RANKL-induced PLCg phos-
phorylation. Phosphorylation of PLCg activates NFATc1 through calcium/calcineurin signaling. Thus,
PLCg and BLNK form a bridge linking the RANKL and costimulatory pathways, presumably on the cell
membrane. In addition to responding to stimuli from osteoblasts and immune cells, osteoclast precursors
also release TNF and IL-1, which directly stimulate NF-kB/c-Fos/NFATc1 to stimulate osteoclast differen-
tiation. This can set up a self-amplifying autocrine cycle (Boyce et al., 2006) to induce more osteoclast
formation and augment the effects of TNF and IL-1 to induce osteoclast formation through upregulation
of RANKL expression by osteoblasts (not shown).Bone remodeling typically begins follow-
ing the differentiation of marrow-derived
osteoclast precursors (OCPs) into osteo-
clasts in response to many influences,
including mechanical strain, hormones,
growth factors, and cytokines. The pro-
cess is largely regulated by osteoblastic
cells and perhaps T and B cells, which
are induced to express receptor activator
of NF-kB ligand (RANKL) and/or its cog-
nate inhibitor, osteoprotegerin (OPG), in
response to these influences. RANKL
binds to its receptor, RANK, on the sur-
face of OCPs, activating signaling through
NF-kB, c-Fos, phospholipase Cg (PLCg),
and nuclear factor of activated T cells c1
(NFATc1) (Figure 1) to induce differentia-
tion of OCPs into osteoclasts (Takaya-
nagi, 2007). OPG binds to RANKL and284 Cell Metabolism 7, April 2008 ª2008 Elsprevents its interaction with RANK to limit
bone degradation.
Another osteoclastogenic pathway is
activated in OCPs by so-called costimula-
tory immune-mediated signaling through
receptors, including osteoclast-associ-
ated receptor (OSCAR) and triggering
receptor expressed in myeloid cells 2
(TREM2). These receptors activate immu-
noreceptor tyrosine-based activation mo-
tifs (ITAMs) in adaptor molecules such as
DNAX-activating protein 12 (DAP12) and
Fc receptor common g subunit (FcRg) in
OCPs and lead to calcium-dependent
activation of NFATc1 (Takayanagi, 2007),
also through PLCg (Figure 1). The ligands
for these receptors in OCPs have not
been identified, but they are likely to in-
clude immune complexes and proteinsevier Inc.that activate immune responses. Costimu-
latory signaling is required for osteo-
clast formation during embryonic devel-
opment and is activated in inflammatory
bone diseases and during immune
responses, similar to RANKL/RANK sig-
naling, to increase osteoclast formation.
This typically leads to enhanced bone
loss. However, a direct link between these
two pathways or how enhanced and
deficient immune responses might be
associated with bone loss has not been
identified.
To identify shared mechanisms and
crosstalk between the immune and bone
systems, Shinohara et al. (2008) per-
formed a genome-wide screen of mRNAs
for nonreceptor tyrosine kinases that
might phosphorylate proteins in the PLCg
pathway. They found that osteoclasts
express high levels of the tyrosine kinases
Bruton (Btk;mutationsof thisgene result in
immunodeficiency) and Tec, which have
unique functions in B cells (Ellmeier et al.,
2000). They examined Btk/Tec double
knockout (dKO)mice and found that these
mice had moderate osteopetrosis, as-
sociated with decreased numbers of
osteoclasts. RANKL-induced tyrosine
phosphorylation of PLCg was markedly
suppressed in dKO OCPs, which had
almost no calcium oscillations required
for induction of NFATc1. The authors
surmised that since both costimulatory
signals and RANKL/RANK signaling acti-
vate PLCg, one or more scaffolding pro-
teinsmight linkaBtk/Tecenzymecomplex
with PLCg.
In B cells, ITAM associates with Syk,
which associates with and phosphory-
lates scaffold proteins, such as BLNK.
Shinohara et al. found that Btk colocalized
with BLNK on the plasma membrane of
OCPs after RANKL treatment. This was
not observed in OCPs from DAP12/FcRg
dKO mice (which also have osteopetro-
sis), suggesting that ITAMs are also re-
quired for the formation of the Btk/BLNK
complex. Btk and Tec kinases were phos-
phorylated in response to RANKL even in
the DAP12/FcRg dKO OCPs. Shinohara
et al. concluded that activation of Btk by
RANKL and activation of BLNK by ITAM
signals are both required for the associa-
tion of Btk with BLNK, linking these two
pathways for the first time. Finally, the
authors found that a Tec kinase inhibitor
attenuated LPS- and RANKL-induced os-
teoclast formation and bone loss in mice,
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activity in osteoclast formation.
These findings indicate that Btk and
Tec together have essential functions
in osteoclast differentiation as well as
in immune responses. They not only link
RANKL and costimulatory signaling di-
rectly in OCPs but also add another piece
to the puzzle of how bone and immune
cells interact to regulate bone
remodeling in the growing field of os-
teoimmunology (Figure 1). Previously
known pieces are that cells other than os-
teoblasts express RANKL, including sy-
novial lining cells and activated T cells in
inflamed joints. These cells can regulate
the differentiation of not only OCPs but
also dendritic and B cells (Takayanagi,
2007). RANKL/RANK/NF-kB signaling is
also required for lymph node formation,
at least in mice. Osteoblasts and B cells
secrete OPG to limit OCP differentiation
(Weitzmann and Pacifici, 2007). The
proinflammatory cytokines tumor necro-
sis factor (TNF) and interleukin-1 (IL-1)
are released at sites of inflammation in
bones (Yao et al., 2008) and stimulate
osteoclast formation indirectly by induc-
ing RANKL expression by osteoblastic
cells. TNF and IL-1 can also induce oste-
oclast formation directly by binding to
their receptors on OCPs (Boyce et al.,
2006). These actions can result in self-
amplifying autocrine and paracrine cycles
to upregulate osteoclast formation at sites
of inflammation (Figure 1) independently
of RANKL/RANK. A further twist to the
story is that OPG and RANKL are ex-
pressed in atherosclerotic plaques, which
are now recognized as sites of immune re-
actions, and patients with atherosclerosis
have reduced bone mineral density (Col-
lin-Osdoby, 2004). OPG may also limitcalcification of atherosclerotic plaques
(Montecucco et al., 2007). It is not yet
clear what the role of RANKL is in athero-
sclerosis, but these findings suggest that
osteoimmunology may extend beyond
the bone marrow and joints.
Cytokine expression is increased not
only in erosive joint diseases but also after
menopause; this is associatedwith activa-
tion of T cells after ovariectomy in mice
(Roggia et al., 2001). Immune responses
are activated in rheumatoid arthritis as
part of an autoimmune reaction, but what
activates them following sex-steroid defi-
ciency remains amystery; T cell activation
raises the possibility of an immunologic
basis for menopause-related bone loss.
Could it be that only 35%–40% of post-
menopausal women develop osteoporo-
sis because they have enhanced immune
responses to something that has yet
to be identified, while the remainder do
not?
Shinohara et al. (2008) have shown that
the Tec family of kinases shares similar
functions with NF-kB proteins to regulate
B cell and osteoclast differentiation;
deficiency of Btk/Tec or NF-kB is also as-
sociated with immunodeficiency. Exactly
how these two signaling systems work to-
gether to induce osteoclast differentiation
is currently unclear. For example, it is not
known whether one acts earlier than the
other or whether osteoblastic cells inter-
act with the cells expressing ligands that
activate OSCAR and other receptors.
The nature of these latter cells has not
been defined, but they are likely to be
hematopoietic rather than osteoblastic.
Recent studies have described some
unexpected functions for osteoclasts,
including regulation of osteoblasts, hema-
topoietic stem cell egression from boneCell Metamarrow, and angiogenesis (Boyce et al.,
2007), and for osteoblasts, including
glucose metabolism, insulin sensitivity, and
energy conservation (Semenkovich and
Teitelbaum, 2007), in addition to these
cells’ functions in bone remodeling to reg-
ulate immune and other responses. Now
is a good time to take a fresh look for other
possible links between bone cells and
common diseases of aging.
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